Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells.
OBJECTIVE
To investigate the effect of alternol on pancreatic cancer cells.


METHODS
Pancreatic cancer cells PANC-1 and BxPC3 were treated with various concentrations of alternol for 24, 48 and 72 h. Cell proliferation was measured by cell counting. Cell cycle distribution and mitochondrial membrane potential were determined by flow cytometry. Apoptosis was determined by a TdT-mediated dUTP nick end labeling assay and Hoechst staining. Expression of caspase 3, Bcl-2, p53 and p21 was measured by western blotting.


RESULTS
Alternol showed dose- and time-dependent inhibition of the proliferation of PANC-1 and BxPC3 cells in vitro. Alternol induced apoptosis and cell cycle arrest at S phase and decreased mitochondrial membrane potential. Alternol activated caspase 3, upregulated p53 and p21 expression, and downregulated Bcl-2 expression in a dose-dependent manner.


CONCLUSIONS
Our results suggested that alternol is a candidate for treatment of pancreatic cancer.
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China.
Pei-Fang
PF
Cong
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China.
Ying-Chun
YC
Qu
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China.
Jie-Peng
JP
Chen
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China.
Li-Li
LL
Duan
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China.
Cheng-Jiang
CJ
Lin
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China.
Xiao-Lin
XL
Zhu
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China.
Jesse
J
Li-Ling
Pei-Fang Cong, Ying-Chun Qu, Cheng-Jiang Lin, Xiao-Lin Zhu, Mei-Xia Zhang, Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang 110122, Liaoning Province, China.
Mei-Xia
MX
Zhang
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology*; D006801:Humans; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D059807:S Phase Cell Cycle Checkpoints / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
C526095:Alternol; D000970:Antineoplastic Agents; C000595707:BCL2 protein, human; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D006576:Heterocyclic Compounds, 4 or More Rings; D019253:Proto-Oncogene Proteins c-bcl-2; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C505407:CASP3 protein, human; D053148:Caspase 3
Alternol; Apoptosis; Cell cycle; Chemotherapy; Pancreatic cancer